Amneal Pharmaceuticals, Inc. Free Cash Flow 2016–2025
Amneal Pharmaceuticals, Inc. reported $269.93M of free cash flow for fiscal 2025. That was 11.0% higher than fiscal 2024. Compared with fiscal 2020, the change was -16.3%.
| Fiscal year | Free Cash Flow | Change (YoY) |
|---|---|---|
| FY 2025 | $269.93M | +11.0% |
| FY 2024 | $243.18M | -19.6% |
| FY 2023 | $302.36M | +1517.5% |
| FY 2022 | $18.69M | -90.4% |
| FY 2021 | $194.09M | -39.8% |
| FY 2020 | $322.56M | +809.3% |
| FY 2019 | $-45.48M | -127.2% |
| FY 2018 | $167.14M | +19.9% |
| FY 2017 | $139.42M | +1911.5% |
| FY 2016 | $-7.70M | — |
Source: Amneal Pharmaceuticals, Inc. SEC filings — cash flow statement (10-K). Computed deterministically; refreshed nightly (last updated August 2, 2026). Open AMRX 10-K filings at SEC EDGAR · Methodology · Download CSV.
How to read this history
Amneal Pharmaceuticals, Inc. reported $269.93M of free cash flow for fiscal 2025. That was 11.0% higher than fiscal 2024. Compared with fiscal 2020, the change was -16.3%. Values remain missing when the cached filing does not disclose a comparable line item; they are never estimated. Stock splits, reorganizations and fiscal-calendar changes can reduce comparability.
Prepared and reviewed by the stockportfolio.pro research desk. Corrections: support@stockportfolio.pro.
See the full picture for Amneal Pharmaceuticals, Inc.
Complete income statement, balance sheet and cash flow with trend on every row, 48 quarters, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open the interactive view — freeAmneal Pharmaceuticals, Inc. — frequently asked questions
What is Amneal Pharmaceuticals, Inc.'s free cash flow?
Amneal Pharmaceuticals, Inc. (AMRX) reported free cash flow of $269.93M for fiscal year 2025, per its SEC filings.
Where does this data come from?
Figures are computed from Amneal Pharmaceuticals, Inc.'s official SEC filings (cash flow statement (10-K)), refreshed nightly. Not investment advice.